Source: Biomedicine & Pharmacotherapy. Unidade: FMRP
Subjects: INSUFICIÊNCIA RENAL AGUDA, COVID-19, QUIMIOTERAPIA, HOSPITALIZAÇÃO, RESPIRAÇÃO ARTIFICIAL, PRÓPOLIS, RESULTADO DE TRATAMENTO
ABNT
SILVEIRA, Marcelo Augusto Duarte et al. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial. Biomedicine & Pharmacotherapy, v. 38, 2021Tradução . . Disponível em: https://doi.org/10.1016/j.biopha.2021.111526. Acesso em: 22 set. 2023.APA
Silveira, M. A. D., De Jong, D., Berretta, A. A., Galvão, E. B. dos S., Ribeiro, J. C., Cerqueira-Silva, T., et al. (2021). Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial. Biomedicine & Pharmacotherapy, 38. doi:10.1016/j.biopha.2021.111526NLM
Silveira MAD, De Jong D, Berretta AA, Galvão EB dos S, Ribeiro JC, Cerqueira-Silva T, Amorim TC, Conceição LFMR da, Gomes MMD, Teixeira MB. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial [Internet]. Biomedicine & Pharmacotherapy. 2021 ; 38[citado 2023 set. 22 ] Available from: https://doi.org/10.1016/j.biopha.2021.111526Vancouver
Silveira MAD, De Jong D, Berretta AA, Galvão EB dos S, Ribeiro JC, Cerqueira-Silva T, Amorim TC, Conceição LFMR da, Gomes MMD, Teixeira MB. Efficacy of Brazilian green propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial [Internet]. Biomedicine & Pharmacotherapy. 2021 ; 38[citado 2023 set. 22 ] Available from: https://doi.org/10.1016/j.biopha.2021.111526